arrow
Y

Yuta Sekino

National Cancer Center Hospital
H指数:13
被引数:769

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of Methods for Intersegmental Plane Preparation: Supplemental Analysis of JCOG0802/WJOG4607L

各节段平面制备方法的比较:JCOG0802/WJOG4607L的补充分析

2026-09-170
PRE
Definitive IMRT alone with reduced prophylactic nodal irradiation for Early-Stage Oropharyngeal Cancer: JCOG1208

早期口咽癌采用明确的IMRT单放联合缩小的预防性淋巴结照射:JCOG1208

2026-06-280
OA
Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial

膀胱保留疗法联合阿特珠单抗和放射疗法 (bpt-art) 治疗浸润性膀胱癌: 来自多中心,开放标签,前瞻性2期试验的最终分析

2026-01-170
OAAI
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110)

乳腺癌寡转移的转移导向疗法随机对照试验:OLIGAMI试验(JCOG2110)

2026-01-010
PRE
Corrigendum to ‘Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)’ [Journal of Thoracic Oncology Vol. 20 No. 7 (2025) 912–927]

勘误:‘Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)’ [Journal of Thoracic Oncology Vol. 20 No. 7 (2025) 912–927]

2025-10-070
PRE
Longitudinal assessment of functional independence of older adults after lung cancer surgery: Final results of the JCOG1710A prospective cohort study

肺癌术后老年患者功能独立性的纵向评估:JCOG1710A前瞻性队列研究的最终结果

2025-05-300
OA
Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial

段切除术后的局部区域复发的危险因素:JCOG0802/WJOG4607L试验的补充分析

2025-02-016
PRE
Combined Molecular Subclass and Immune Phenotype Correlate to Atezolizumab Plus Radiation Therapy Response in Invasive Bladder Cancer: BPT-ART Phase 2 Study

联合分子亚类和免疫表型与阿替利珠单抗联合放疗在浸润性膀胱癌中的疗效相关:BPT-ART II期研究

2025-01-010
PRE
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
2024-11-011
PRE
A Randomized Controlled Trial of Metastasisdirected Therapy for Oligometastases in Breast Cancer (OLIGAMI trial; JCOG2110)
2024-05-020
PRE
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial

在日本,肺段切除术与肺叶切除术在放射学纯实性的小型周围型非小细胞肺癌中的比较 (JCOG0802/WJOG4607L): 多中心,开放标签,3期试验的事后补充分析

2024-02-0115
PRE
Long-Term Follow-up of a Randomized Controlled Trial on Accelerated Radiation Therapy Versus Standard Fractionated Radiation Therapy for Early Glottic Cancer (JCOG0701A3)

加速放疗与标准分次放疗治疗早期声门型喉癌随机对照试验的长期随访 (JCOG0701A3)

2023-12-013
OAAI
Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE)
2023-11-060
OAAI
Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial

膀胱保留疗法联合阿特珠单抗和放射疗法 (bpt-art) 治疗浸润性膀胱癌的疗效和安全性: 一项多中心,开放标签,前瞻性2期试验的中期分析

2023-11-018
OAAI
Risk factors for loss of pulmonary function after wedge resection for peripheral ground-glass opacity dominant lung cancer
2023-10-312
PRE